Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agents

Clinical and Applied Thrombosis/Hemostasis

Volumn 5, Issue SUPPL. 1, 1999, Pages

  Jeske, Walter P ^a   Jay, Allison M ^a   Haas, Sylvia ^b   Walenga, Jeanine M ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Heparin induced thrombocytopenia; Low molecular weight heparin; Pentasaccharide; Thrombin inhibitors

Indexed keywords

DANAPAROID; HEPARIN;

ANTIGEN BINDING; CONFERENCE PAPER; CONFORMATIONAL TRANSITION; DRUG EFFECT; DRUG PROTEIN BINDING; HUMAN; MOLECULAR RECOGNITION; MOLECULAR SIZE; PRIORITY JOURNAL; SEROTONIN RELEASE; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA;

EID: 0032732652     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/10760296990050s110     Document Type: Conference Paper

References (28)

1. Aster RH. Heparin-induced thrombocytopenia: understanding improves but questions remain. J Clin Lab Med 1996;127:418.
2. Wallis DE, Lewis BE, Pifarré R, et al. Active surveillance for heparin-induced thrombocytopenia and thromboembolism. American College of Chest Physicians, October 30-November 3, 1994.
3. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992;68:95.
4. Home MK, Alkins BR. Platelet binding of IgG from patients with heparin-induced thrombocytopenia. J Clin Lab Med 1996;127:435.
5. Chong BH, Pilgrim RL, Cooley MA, et al. Increased expression of platelet IgG Fc receptors in immune heparin-induced thrombocytopenia. Blood 1993;81:988.
6. Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost 1992;67:545.
7. Walenga JM, Koza MJ, Lewis BE, et al. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb Hemost 1996;2(Suppl 1):S21.
8. Amiral J, Wolf M, Fischer A, et al. Pathogenicity of IgA and/or IgM antibodies to UFH-PF 4 complexes with UFH-induced thrombocytopenia. Br J Haematol 1996;92:954.
9. Walenga JM, Lewis BE, Hoppensteadt DA, et al. Management of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Clin Appl Thromb Hemost 1997;3(Suppl 1):53.
10. Nand S, Robinson J. Plasmapheresis in the management of heparin associated thrombocytopenia with thrombosis. Am J Hematol 1988;28:204.
11. Lewis BE, Rao RC, Robinson JA, et al. Early plasmapheresis reduces mortality in patients with heparin-induced thrombosis. Blood 1995;86:919a.
12. Huisse MG, Guillin MC, Bezeaud A, et al. Heparin-associated thrombocytopenia. In vitro effects of different molecular weight heparin fractions. Thromb Res 1982;27:485.
13. Gouault-Heilmann M, Payen D, Contant G, et al. Thrombocytopenia related to synthetic heparin analogue therapy. Thromb Haemost 1985;54:557.
14. Roussi JH, Houbouyan LL, Goguel AF. Use of low-molecular-weight heparin in heparin-induced thrombocytopenia with thrombotic complications. Lancet 1984;26:1183.
15. Massonnet-Castel S, Pelissier E, Dreyfus G, et al. Low-molecular-weight heparin in extracorporeal circulation. Lancet 1984;26:1182.
16. Robitaille D, Leclerc JR, Laberge R, et al. Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia. J Thorac Cardiovasc Surg 1992;103:597.
17. Eichinger S, Kyrle PA, Brenner B, et al. Thrombocytopenia associated with low-molecular-weight heparin. Lancet 1991;337:1425.
18. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330.
19. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993;70:554.
20. Makhoul RG, Greenberg CS, McCann RL. Heparin-associated thrombocytopenia and thrombosis: a serious clinical problem and potential solution. J Vasc Surg 1986;4:522.
21. Haas S, Walenga JM, Jeske WP, et at. Heparin-induced thrombocytopenia: clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors. Clin Appl Thromb Hemost 1999;5:52.
22. Demers C, Ginsberg JS, Brill-Edwards P, et al. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 1991;78:2194.
23. Lewis BE, Leya FS, Wallis D, et al. Failure of ancrod in the treatment of heparin-induced arterial thrombosis. Can J Cardiol 1994;10:559.
24. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99:73.
25. Lewis BE. Preliminary results of a prospective randomized controlled trial of argatroban vs. conventional therapy for heparin-induced thrombocytopenia. Presented at the Argatroban - A Novel Antithrombotic Drug for the Treatment of Heparin-induced Thrombocytopenia Symposium; June 12, 1997; Florence, Italy.
26. Walenga JM. Factor Xa inhibition in mediating antithrombotic actions: Application of a synthetic heparin pentasaccharide [doctoral thesis]. Paris: Universite Pierre et Marie Curie; 1987.
27. Ahmad S, Jeske WP, Walenga JM, et al. Synthetic heparin pentasaccharides do not cause platelet activation by heparin antibodies. Clin Appl Thromb Hemost 1999;5:252.
28. Sheridan D, Carter C, Kelton JG. A diagnostic test for UFH induced thrombocytopenia. Blood 1986;67:27.